ArticleProceedings of the National Academy of Sciences of the United States of America2000
Adeno-associated virus site-specifically integrates into a muscle-specific DNA region.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 89 citations in OpenAlex.
- AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects.Gene therapy · 2025Review
- Exploring AAV-Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Neurosurgical gene therapy for central nervous system diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- Recombination in eukaryotic single stranded DNA viruses.Viruses · 2011Review
- Computationally designed adeno-associated virus (AAV) Rep 78 is efficiently maintained within an adenovirus vector.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Cardiac gene therapy with SERCA2a: from bench to bedside.Journal of molecular and cellular cardiology · 2011Review
- Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoter.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Substitution of adeno-associated virus Rep protein binding and nicking sites with human chromosome 19 sequences.Virology journal · 2010Article
- Adeno-associated virus: a key to the human genome?Future virology · 2010Article
- Cardiac gene therapy.Seminars in thoracic and cardiovascular surgery · 2010Review
- Transcriptional analysis of the adeno-associated virus integration site.Journal of virology · 2009Article
- Site-specific integration of adeno-associated virus involves partial duplication of the target locus.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Gene therapy using adeno-associated virus vectors.Clinical microbiology reviews · 2008Review
- Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.Pharmaceutical research · 2008Review
- Relative influence of the adeno-associated virus (AAV) type 2 p5 element for recombinant AAV vector site-specific integration.Journal of virology · 2008Article
- Replication initiator protein NS1 of the parvovirus minute virus of mice binds to modular divergent sites distributed throughout duplex viral DNA.Journal of virology · 2007Article
- Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?International journal of nanomedicine · 2007Review
- Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins.Journal of virology · 2005Article
- Adeno-associated virus: from defective virus to effective vector.Virology journal · 2005Review
- Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The nonpathogenic human virus adeno-associated virus type 2 (AAV) has evolved the potentially unique strategy to establish latency by site-specifically integrating its genome into human chromosome 19 (19q13.3-qter) at a locus designated AAVS1. This nonhomologous, site-specific recombination of viral DNA with the human genome provides a basis for developing targeted gene therapy vectors. To assess whether the region surrounding AAVS1 might have contributed to the selection of the specific integration site, we have investigated this locus. Here, we show that AAVS1 is closely linked to the slow skeletal troponin T gene, TNNT1, which has been mapped previously to 19q13.4. In support of this idea, we demonstrate that site-specific AAV DNA integration can result in the formation of TNNT1-AAV junctions. The question now arises whether muscle represents a natural target tissue for latent AAV infection. This possibility is of additional interest in view of recent observations that muscle tissue is particularly well suited for AAV-mediated gene transfer. The question also occurs whether latent infection by AAV can lead to phenotypic changes of the multinucleated muscle fiber cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.